Affini-T Therapeutics is a venture-backed biotechnology company committed to engineering best-in-class T cell therapies intended to provide patients suffering from cancer with curative therapeutics.

We use a validated platform to select high affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies.

Led by our team of seasoned drug developers and immunotherapy trailblazers, Affini-T leverages groundbreaking gene editing and synthetic biology to engineer novel T cell therapies designed to eradicate tumors.
FOR MORE INFORMATION, PLEASE CONTACT US HERE.

© AFFINI-T THERAPEUTICS INC.